Hyperthermic <i>vs</i> normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study
HIVeC with MMC demonstrated comparable oncologic outcomes to normothermic MMC in Ir-NMIBC, with a longer time to recurrence and similar tolerability. These findings suggest its potential use in selected patients, but should be interpreted with caution due to the retrospective design and limited sample size.
Authors
- Rita Marques (ORCID: https://orcid.org/0009-0000-5557-7868)
- António Matos (ORCID: https://orcid.org/0000-0001-9386-0349)
- Carlos Rabaça (ORCID: https://orcid.org/0000-0002-3304-3803)
- Ricardo Godinho (ORCID: https://orcid.org/0000-0003-3730-7682)
- D. Brito (ORCID: https://orcid.org/0000-0002-7960-774X)
- Ana Maria Ferreira (ORCID: https://orcid.org/0000-0003-1764-8842)
- José Pereira (ORCID: https://orcid.org/0000-0003-1362-1263)
- Bruno Jorge Pereira (ORCID: https://orcid.org/0000-0001-6537-1388)
- Mário Lourenço (ORCID: https://orcid.org/0000-0001-9303-6245)
- Pedro Peralta
Institutions
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
Publication Details
- Journal
- Archivio Italiano di Urologia e Andrologia
- Published
- 2025-11-05
- DOI
- https://doi.org/10.4081/aiua.2025.14167
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00